





WORLD ODISSEY

OPHTHALMOLOGY

BRINZOLAMIDE 1%
OPHTHALMIC
SUSPENSION FOR
CHRONIC OPEN ANGLE
GLAUCOMA OR
OCULAR
HYPERTENSION



CLINICAL TRIALS FRONTIER




Ophthalmology

MOLECULE	INDICATION	Phase	No. of Sites	No. of Patients
Brinzolamide 1% ophthalmic suspension	Chronic open angle glaucoma or ocular hypertension	BA/BE	14	200
Nepafenac Ophthalmic Suspension 0.3%	Pain and Inflammation in the Eye associated with Cataract Surgery	III	18	278
Maquiday (MAQUIBRIGHT®)	Treatment of dry eyes and fatigue	III	120	120
Intracameral Mahaflox 0.5% (Moxifloxacin)	Post cataract endophthalmitis	IV	4	100

Advancements in Ophthalmology - Ongoing Clinical Trials

Ophthalmology



Conclusion

The ongoing clinical trials in ophthalmology highlight the continuous efforts to enhance vision care and address a range of eye-related conditions. From the exploration of Brinzolamide for glaucoma and ocular hypertension to Nepafenac's role in post-cataract surgery care and the innovative approach of Maquiday for dry eyes and fatigue, these trials represent a commitment to advancing ophthalmic treatments. Additionally, the investigation of Intracameral Mahaflox for preventing endophthalmitis post-cataract surgery contributes to the ongoing efforts to improve surgical outcomes and enhance patient safety in ophthalmic procedures.